Page last updated: 2024-12-10

3-amino-5-morpholinomethyl-2-oxazolidinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-amino-5-morpholinomethyl-2-oxazolidinone: a metabolite of furaltadone [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-amino-5-morpholinomethyl-2-oxazolidinone : A member of the class of oxazolidinones that is 3-amino-1,3-oxazolidin-2-one substituted by a morpholin-4-ylmethyl group at position 5. It is the metabolite of furaltadone, a broad-spectrum antibacterial drug which was widely used as an additive in livestock and aquaculture feed. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3016406
CHEBI ID143240
SCHEMBL ID2780968
MeSH IDM0490205

Synonyms (30)

Synonym
einecs 256-068-9
FT-0662133
3-amino-5-(morpholinomethyl)oxazolidin-2-one
CHEBI:143240
3-amino-5-morpholinomethyl-2-oxazolidinone
3-amino-5-(4-morpholinomethyl)oxazolidin-2-one
3-amino-5-(morpholin-4-ylmethyl)-1,3-oxazolidin-2-one
amoz
3-amino-5-morpholino-methyl-1,3-oxazolidone
43056-63-9
3-amino-5-[(morpholin-4-yl)methyl]-1,3-oxazolidin-2-one
AS-7038
AKOS015903481
3-amino-5-(4-morpholinylmethyl)-2-oxazolidinone
SCHEMBL2780968
2-oxazolidinone, 3-amino-5-(4-morpholinylmethyl)-
amoz, certified reference material, tracecert(r)
mfcd04038841
amoz, vetranal(tm), analytical standard
3-amino-5-morpholinomethyl-2-oxazolidinone (amoz) 10 microg/ml in acetonitrile
3-amino-5-morpholinomethyl-2-oxazolidinone (amoz)
A912939
HY-131146
3-amino-5-morpholinomethyl-2-oxazolidinone amoz
BCP27761
-amino-5-(4-morpholinomethyl)oxazolidin-2-one
CS-0129538
E78659
DTXSID20962873
3-amino-5-morpholinomethyl-1,3oxazolidone
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
xenobiotic metaboliteAny metabolite produced by metabolism of a xenobiotic compound.
marine xenobiotic metaboliteAny metabolite produced by metabolism of a xenobiotic compound in marine macro- and microorganisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
oxazolidinoneAn oxazolidine containing one or more oxo groups.
morpholinesAny compound containing morpholine as part of its structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (18.18)29.6817
2010's9 (81.82)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.76 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index5.14 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]